#Spain #Barcelona #COPD #Altesa BioSciences #Vapendavir

Altesa BioSciences Presents New Data on Vapendavir at ERS 2026

At the European Respiratory Society (ERS) International Congress 2026 held in Barcelona, Altesa BioSciences showcased groundbreaking clinical data regarding its investigational antiviral therapy, Vapendavir. This promising treatment has been demonstrated to significantly reduce key inflammatory biomarkers in patients suffering from Chronic Obstructive Pulmonary Disease (COPD) who are also experiencing rhinovirus infections.

Significant Findings

During an oral presentation titled "Inflammatory biomarkers are reduced by vapendavir treatment in rhinovirus-challenged COPD patients," Dr. Sebastian Johnston from Imperial College London detailed the study's findings. Previous research presented at the ERS 2025 had already established that Vapendavir was effective in reducing viral load, the severity of illness, and even improving the overall quality of life in COPD patients. These new results further emphasize the treatment's capability in mitigating inflammation, which is crucial for patient recovery.

Dr. Johnston explained, "The current findings elucidate why patients on Vapendavir exhibited less severe symptoms during this study. We are witnessing a tangible decrease in the inflammatory response within the airway rather than solely a reduction in viral load." This statement highlights the dual role of Vapendavir as both an antiviral and an anti-inflammatory agent, which could significantly shift treatment strategies for COPD patients.

Research Scope and Results

The Phase 2a study included COPD patients who were experimentally exposed to rhinovirus. Following this exposure, participants received either Vapendavir or a placebo. The analysis of nasal lavage samples revealed marked reductions in two vital inflammatory molecules, IP-10/CXCL10 and GM-CSF, among those who received Vapendavir. Additionally, trends indicated lower nasal concentrations of other biomarkers, IFN-α2a and IFN-λ1/IL-29, though they did not achieve statistical significance.

Dr. Katharine Knobil, Chief Medical Officer at Altesa BioSciences, commented, "These collective results affirm the link between the antiviral capabilities of Vapendavir and the decrease in airway inflammation observed in COPD patients experiencing rhinovirus infections. Acute exacerbations from COPD lead to hospitalizations and exacerbate lung function loss."

The Future of Vapendavir

As an investigational oral medication, Vapendavir is in late-stage clinical development, and should it receive approval, it has the potential to transform the management of COPD exacerbations caused primarily by rhinovirus infections. Altesa is actively conducting the Phase 2b CARDINAL trial, which aims to enroll 900 participants from across the United States and the United Kingdom. Participants will be closely monitored and randomized to either different doses of Vapendavir or a placebo following confirmed rhinovirus infection.

The primary goal of the CARDINAL study is to assess improvements in respiratory symptoms, with additional metrics focused on the quality of life, health care resource utilization, and lung function parameters. This trial is crucial for validating Vapendavir's efficacy as a comprehensive treatment for COPD exacerbations.

About Altesa BioSciences

Altesa BioSciences is at the forefront of clinical-stage pharmaceutical development, specializing in treatments for chronic lung diseases such as COPD and asthma. Their mission is to alleviate the burdens of these conditions by targeting the underlying causes of exacerbations through innovative therapies. For more information, visit www.altesa.com.

In conclusion, the findings presented by Altesa BioSciences at the ERS 2026 Congress underscore the importance of Vapendavir in clinical practice and its potential to revolutionize the treatment landscape for COPD patients. As research progresses, the hope is to offer significant improvements in patient outcomes and a better quality of life for those afflicted by chronic lung diseases.